Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
AML
JAK2
MPN
accelerated phase
blast phase
essential thrombocythaemia
polycythaemia vera
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
13
07
2023
received:
30
04
2023
accepted:
21
07
2023
medline:
5
10
2023
pubmed:
2
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estimated survival rates for such blast phase patients is frequently reported as less than 6 months. No specific immunological, genomic or clinicopathological signature currently exists that accurately predicts the risk and timing of transformation, which frequently induces a high degree of anxiety among patients and clinicians alike. Within this review article, we provide an up-to-date summary of current understanding of the underlying pathogenesis of accelerated and blast phase disease and discuss current therapeutic approaches and realistic outcomes. Finally, we discuss how the horizon may look with the introduction of more novel agents into the clinical arena.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-181Informations de copyright
© 2023 British Society for Haematology and John Wiley & Sons Ltd.
Références
Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018;32(5):1200-1210.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, et al. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020;126(19):4322-4331.
Masarova L, Bose P, Zahr AA, Cortes J, Kantarjian H, Verstovsek S. Do we need to re-define accelerated phase of myelofibrosis? Correlation between blast percentage in myelofibrosis and outcomes. Clin Lymphoma Myeloma Leuk. 2017;17:S352.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated phase of myeloproliferative neoplasms. Acta Haematol. 2021;144(5):484-499.
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881.
Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513.
Iurlo A, Cattaneo D, Gianelli U. Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options. Int J Mol Sci. 2019;20(8):E1839.
Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017;92(7):1118-1128.
Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-276.
Luque Paz D, Jouanneau-Courville R, Riou J, Ianotto JC, Boyer F, Chauveau A, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887-4897.
Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291-302.
Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631-1642.
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318.
Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770.
Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416-1430.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, et al. Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. Am J Hematol. 2022;97(7):846-855.
Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, et al. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019;9(2):12.
Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24(6):1146-1151.
Jäger R, Gisslinger H, Berg T, Passamonti F, Cazzola M, Rumi E, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms at transformation to acute myeloid leukemia. Blood. 2009;114(22):435.
Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S. Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives. Cell. 2021;10(12):3551.
Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018;2(4):370-380.
Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012;26(5):1135-1137.
Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011;118(1):167-176.
Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci. 2014;111(50):E5401-E5410. https://doi.org/10.1073/pnas.1407792111
Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, et al. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica. 2017;102(1):e11-e14.
Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375-379.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-2228.
Li B, An W, Wang H, Baslan T, Mowla S, Krishnan A, et al. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood. 2022;139(25):3630-3646.
Brierley C, Psaila B. A tale of two alleles: TP53 and transformation in MPNs. Blood. 2022;139(25):3567-3568.
Rodriguez-Meira A, Norfo R, Wen WX, Chédeville AL, Rahman H, O'Sullivan J, et al. Deciphering TP53 mutant cancer evolution with single-cell multi-omics. Cancer Biol Ther. 2022. https://doi.org/10.1101/2022.03.28.485984
Celik H, Krug E, Zhang CR, Han W, Issa N, Koh WK, et al. A humanized animal model predicts clonal evolution and therapeutic vulnerabilities in myeloproliferative neoplasms. Cancer Discov. 2021;11(12):3126-3141.
Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol. 2021;12:683401.
Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709-715.
Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm. 2015;2015:1-16.
Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(2):279-281.
Ortí G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, et al. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023;98:628-638.
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, et al. GITMO registry study on allogeneic transplantation in patients aged ≥60 years from 2000 to 2017: improvements and criticisms. Transplant Cell Ther. 2022;28(2):96.e1-96.e11.
Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology. 2021;2021(1):254-263.
Polverelli N, Tura P, Battipaglia G, Malagola M, Bernardi S, Gandolfi L, et al. Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. Bone Marrow Transplant. 2020;55(12):2224-2233.
Issa JPJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009;15(12):3938-3946.
Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation: hypermethylation of p15, p16 in Leukaemic transformation of MF. Br J Haematol. 2002;116(3):582-586.
Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116(19):3735-3742.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015;39(9):950-956.
Andriani A, Montanaro M, Voso MT, Villivà N, Ciccone F, Andrizzi C, et al. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leuk Res. 2015;39(8):801-804.
Chen J, Wang K, Xiao Z, Xu Z. Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis. Ann Med. 2023;55(1):348-360.
Mwirigi A, Galli S, Keohane C, Raj K, Radia DH, Harrison CN, et al. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2014;167(5):714-716.
Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020;4(20):5246-5256.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, et al. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020;34(9):2489-2492.
Drummond MW, Gaskell C, Harrison C, Mead AJ, Yap C, Jackson AE, et al. Phazar: a phase Ib study to assess the safety and tolerability of ruxolitinib in combination with azacitidine in advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN [ISRCTN16783472]. Blood. 2020;136(Suppl 1):2-3.
Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 2013;121(14):2725-2733.
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977.
Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, et al. The natural history and treatment outcome of blast phase BCR-ABL− myeloproliferative neoplasms. Blood. 2008;112(5):1628-1637.
Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, et al. Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. Br J Haematol. 2020;188(3):428-437.
Byrne JL, Beshti H, Clark D, Ellis I, Haynes AP, Das-Gupta E, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. Br J Haematol. 2000;108(2):430-433.
McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35(9):2445-2459.
Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1−MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.
Versluis J, Lindsley RC. Transplant for TP53-mutated MDS and AML: because we can or because we should? Hematology. 2022;2022(1):522-527.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53 -mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772-3781.
Sanber K, Ye K, Tsai HL, Newman M, Ambinder A, DeZern A, et al. P572: venetoclax and hypomethylating agent combinations for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. HemaSphere. 2022;6:471-472.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440-1453.
Ilyas R, McCullough K, Badar T, Patnaik MMM, Alkhateeb HB, Mangaonkar AA, et al. CPX-351 for blast-phase myeloproliferative neoplasm (MPN-BP): Mayo Clinic experience in 10 consecutive patients. Blood. 2022;140(Suppl 1):9704-9705.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684-2692.
Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302-1309.
Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, et al. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020;4(21):5336-5342.
Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, et al. Clinical outcomes of IDH2 -mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020;190(1):e48-e51. https://doi.org/10.1111/bjh.16709
Wang X, Hu CS, Gillespie V, Krejsa CM, Hoffman R. Navtemadlin (KRT-232), a small molecule MDM2 inhibitor, is more effective than decitabine against myeloproliferative neoplasm-blast phase in a patient-derived Xenograft model. Blood. 2021;138(Suppl 1):3591.
Rampal R, Ramanathan S, Papayannidis C, von Bubnoff N, del Mar Tormo Díaz M, Vidriales MB, et al. An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms. J Clin Oncol. 2022;40(16_suppl):TPS7063.
Platzbecker U, Komrokji RS, Fenaux P, Zeidan AM, Sekeres MA, Savona MR, et al. Imetelstat achieved prolonged, continuous transfusion independence (TI) in patients with heavily transfused non-Del(5q) lower-risk myelodysplastic syndrome (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESAs) within the IMerge phase 2 study. Blood. 2022;140(Suppl 1):1106-1108.
Kuykendall A, Wan Y, Mascarenhas J, Kiladjian JJ, Vannucchi A, Wang J, et al. Favorable overall survival of imetelstat-treated relapsed/refractory myelofibrosis patients compared with closely matched real world data. Ann Hematol. 2022;101:139-146.
Ma W, Balaian L, Mondala P, He Y, Mason C, Pham J, et al. Imetelstat inhibits telomerase and prevents propagation of ADAR1-activated myeloproliferative neoplasm and leukemia stem cells. Blood. 2020;136(Suppl 1):18.
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
Abedin SM, Boddy CS, Munshi HG. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther. 2016;9:5943-5953.
Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, et al. MANIFEST: pelabresib in combination with ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. J Clin Oncol. 2023; JCO2201972. https://doi.org/10.1200/JCO.22.01972
Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017;31(3):678-687.
Handlos Grauslund J, Holmström MO, Jørgensen NG, Klausen U, Weis-Banke SE, El Fassi D, et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms. Front Oncol. 2021;11:637420.
Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, et al. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Sci Transl Med. 2022;14(649):eaba4380.
Grauslund JH, Holmström MO, Martinenaite E, Lisle TL, Glöckner HJ, El Fassi D, et al. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: a first-in-man clinical trial. Front Immunol. 2023;14:1117466.
Hobbs G, Cimen Bozkus C, Moshier E, Dougherty M, Bar-Natan M, Sandy L, et al. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021;5(23):5086-5097.
Reis E, Buonpane R, Celik H, Marty C, Lei A, Jobe F, et al. Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs). Blood. 2022;140(Suppl 1):14-15.
Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Emerging CAR T cell strategies for the treatment of AML. Cancer. 2022;14(5):1241.
Ramos E, Wiita A. Profiling the cell surface of MPN blast phase suggests unique biology and therapeutic targets. Blood. 2022;140(Suppl 1):6735-6736.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, et al. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021;193(5):1004-1008.
Kröger N, Eikema D, Köster L, Beelen D, de Wreede LC, Finke J, et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. Br J Haematol. 2019;185(4):725-732.
Takagi S, Masuoka K, Uchida N, Kurokawa M, Nakamae H, Imada K, et al. Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by Philadelphia chromosome-negative myeloproliferative neoplasms: a nationwide survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016;22(12):2208-2213.
Cahu X, Chevallier P, Clavert A, Suarez F, Michallet M, Vincent L, et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014;49(6):756-760.
Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010;16(4):555-559.